With Friends Like VCs, Who Needs Public Equity?
As NASDAQ investors continue to avoid the biotech sector, many biotechs have recently begun to respond in kind--by avoiding NASDAQ. Many of the largest recent financings by public biotechs have been completed privately.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.